Fuchs' Dystrophy clinical trials at UCSF
2 research studies open to eligible people
Fuchs' dystrophy is a disease that damages the cornea, leading to vision issues. UCSF is conducting research to understand how different treatments affect corneal thickness. These trials include many patients and are performed in multiple locations to ensure comprehensive data.
Descemet Endothelial Thickness Comparison Trial I
open to eligible people ages 18 years and up
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on endothelial cell loss.
Palo Alto, California and other locations
Descemet Endothelial Thickness Comparison Trial II
open to eligible people ages 18 years and up
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
Palo Alto, California and other locations
Last updated: